Business Concentrations

6 Months Ended

Jun. 30, 2025

Business Concentrations [Abstract]

Business concentrations

12. Business concentrations

TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, we changed our business to become a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. As part of the transformation that included the Mayne License Agreement, all results associated with former commercial operations have been reflected as discontinued operations in our condensed consolidated financial statements. Assets and liabilities associated with the commercial business are classified as assets and liabilities of discontinued operations in our consolidated balance sheets. Additional disclosures regarding discontinued operations are provided in Note 2.

For the three and six months ended June 30, 2025, 100% of license revenue related to Mayne Pharma, Theramex and Knight.

As of June 30, 2025, we had a royalty receivable of $3,743 thousand relating to the short-term portion of receivable from Mayne Pharma, Theramex and Knight and $14,840 thousand relating to the long-term portion of royalty receivable which includes royalties recognized from the minimum annual royalty that Mayne Pharma is obligated to pay to us under the Mayne License Agreement.